NCT04859439View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions

Renal Impairment

Interventions

DRUG

DBPR108 tablets

Drug: DBPR108, tablet, oral

Trial Locations (1)

Unknown

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY